04:23 PM EDT, 05/16/2024 (MT Newswires) -- Nuvalent ( NUVL ) said late Thursday the US Food and Drug Administration has designated NVL-655 breakthrough therapy to treat people with ALK-positive non-small cell lung cancer who have been treated with two or more ALK tyrosine kinase inhibitors.

The breakthrough therapy designation for the candidate drug is based on its preliminary safety and activity in the phase 1 of the drug's trial, Nuvalent ( NUVL ) said.

Enrollment in phase 2 of the study is ongoing and it expects to release updated results at a medical meeting in H2.

Price: 73.95, Change: +1.31, Percent Change: +1.80